Clinical Trial Update: Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating 18F-PBR06 PET imaging as a pharmacodynamic endpoint in multiple system atrophy (MSA).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy

Drugs mentioned

• 18F-PBR06

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: MSA | Phase 1, Phase 2 | Status: COMPLETED